Skip to search formSkip to main contentSkip to account menu

MDV 3100

Known as: ASP9785, MDV-3100, MDV3100 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Phenylthiohydantoin
analogs & derivatives

Narrower (1)

enzalutamide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
The emergence of extracellular vesicles in urology: fertility, cancer, biomarkers and targeted pharmacotherapy
Extracellular vesicles (EV) are small membrane-bound vesicles enriched in a selective repertoire of mRNA, miRNA, proteins and… 
2013
2013
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
We read with interest the report from Richards and colleagues ([1][1]) on the potential interactions of abiraterone, eplerenone… 
Review
2013
Review
2013
Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
The rapid approval of several novel agents has given prostate cancer patients and their treating physicians many new and… 
Review
2012
Review
2012
Association of Baseline Corticosteroid with Outcomes in a Multivariate Analysis of the Phase 3 Affirm Study of Enzalutamide (ENZA), An Androgen Receptor Signaling Inhibitor (ARSI)
Review
2012
Review
2012
Current and emerging treatments in the management of castration-resistant prostate cancer
Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years… 
Review
2012
Review
2012
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
2012
2012
In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
Previously available androgen receptor (AR) antagonists (bicalutamide, flutamide, and nilutamide) have limited activity against… 
2011
2011
MDV3100 effects on androgen receptor (AR) signaling and bone marrow testosterone concentration modulation: Apreliminary report.
4501 Background: "Intracrine" androgen signaling is linked to castrate-resistant prostate cancer (CRPC) and a "credentialed… 
Review
2011
Review
2011
Clinical trial update and novel therapeutic approaches for metastatic prostate cancer.
Recurrent prostate cancer (PCa) remains a major clinical challenge. Invasive and metastatic PCa lesions often exhibit a partial… 
Review
2011
Review
2011
Broadening horizons in medical management of prostate cancer
Abstract Hormonal therapy. Testosterone suppression achieved either medically or surgically is the standard initial treatment for… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)